You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
5 April 2024
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
2 April 2024
Abivax reports 2023 financial results and operational update
13 February 2024
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
7 February 2024
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
2 February 2024
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
24 January 2024
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024